The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Global Central Nervous System Biomarkers Market Research Report 2024

Global Central Nervous System Biomarkers Market Research Report 2024

Publishing Date : Jul, 2023

License Type :
 

Report Code : 1382560

No of Pages : 89

Ask Your Query

Synopsis

With extensive ongoing development in personalized medicines and the application of biomarkers in diagnosis, the complexity of the central nervous system paves way for the development of biomarkers to enhance early diagnosis of neurological disorders such as Alzheimer's disease, Parkinson's disease, multiple sclerosis, and other neurological conditions.

According to QYResearch’s new survey, global Central Nervous System Biomarkers market is projected to reach US$ 5946.9 million in 2029, increasing from US$ 3862.5 million in 2022, with the CAGR of 5.9% during the period of 2023 to 2029.

Key companies engaged in the Central Nervous System Biomarkers industry include Merck, Takeda Pharmaceutical, Thermo Fisher Scientific, Avacta Group, Diagenic Asa, Banyan Biomarkers, Eli Lilly, Pfizer and Alseres Pharmaceuticals, etc. Among those companies, the top 3 players guaranteed % supply worldwide in 2022.

When refers to consumption region, % value of Central Nervous System Biomarkers were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Central Nervous System Biomarkers market and estimated to attract more attentions from industry insiders and investors.

Report Scope

This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Central Nervous System Biomarkers market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.

By Company

  •     Merck
  •     Takeda Pharmaceutical
  •     Thermo Fisher Scientific
  •     Avacta Group
  •     Diagenic Asa
  •     Banyan Biomarkers
  •     Eli Lilly
  •     Pfizer
  •     Alseres Pharmaceuticals
  •     Acumen pharmaceuticals
  •     EKF Diagnostics
  •     Abiant
  •     Myriad RBM
  •     Aposense

Segment by Type

  •     Safety Biomarker
  •     Efficacy Biomarker
  •     Validation Biomarker
  •     Other

Segment by Application

  •     Hospitals
  •     Clinics
  •     Others

By Region

  •  North America (United States, Canada)
  • Europe (Germany, France, U.K., Italy, Russia, Nordic Countries, Rest of Europe)
  • Asia-Pacific (China, Japan, South Korea,Southeast Asia, India, Australia, Rest of Asia)
  • Latin America (Mexico, Brazil, Rest of Latin America)
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)

 

The Central Nervous System Biomarkers report covers below items:

Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies' Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source

 

Index

 

   1.1 Study Scope
    1.2 Market Analysis by Type
        1.2.1 Global Central Nervous System Biomarkers Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
        1.2.2 Safety Biomarker
        1.2.3 Efficacy Biomarker
        1.2.4 Validation Biomarker
        1.2.5 Other
    1.3 Market by Application
        1.3.1 Global Central Nervous System Biomarkers Market Growth by Application: 2018 VS 2022 VS 2029
        1.3.2 Hospitals
        1.3.3 Clinics
        1.3.4 Others
    1.4 Study Objectives
    1.5 Years Considered
    1.6 Years Considered

 2 Global Growth Trends
    2.1 Global Central Nervous System Biomarkers Market Perspective (2018-2029)
    2.2 Central Nervous System Biomarkers Growth Trends by Region
        2.2.1 Global Central Nervous System Biomarkers Market Size by Region: 2018 VS 2022 VS 2029
        2.2.2 Central Nervous System Biomarkers Historic Market Size by Region (2018-2023)
        2.2.3 Central Nervous System Biomarkers Forecasted Market Size by Region (2024-2029)
    2.3 Central Nervous System Biomarkers Market Dynamics
        2.3.1 Central Nervous System Biomarkers Industry Trends
        2.3.2 Central Nervous System Biomarkers Market Drivers
        2.3.3 Central Nervous System Biomarkers Market Challenges
        2.3.4 Central Nervous System Biomarkers Market Restraints

 3 Competition Landscape by Key Players
    3.1 Global Top Central Nervous System Biomarkers Players by Revenue
        3.1.1 Global Top Central Nervous System Biomarkers Players by Revenue (2018-2023)
        3.1.2 Global Central Nervous System Biomarkers Revenue Market Share by Players (2018-2023)
    3.2 Global Central Nervous System Biomarkers Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
    3.3 Players Covered: Ranking by Central Nervous System Biomarkers Revenue
    3.4 Global Central Nervous System Biomarkers Market Concentration Ratio
        3.4.1 Global Central Nervous System Biomarkers Market Concentration Ratio (CR5 and HHI)
        3.4.2 Global Top 10 and Top 5 Companies by Central Nervous System Biomarkers Revenue in 2022
    3.5 Central Nervous System Biomarkers Key Players Head office and Area Served
    3.6 Key Players Central Nervous System Biomarkers Product Solution and Service
    3.7 Date of Enter into Central Nervous System Biomarkers Market
    3.8 Mergers & Acquisitions, Expansion Plans

 4 Central Nervous System Biomarkers Breakdown Data by Type
    4.1 Global Central Nervous System Biomarkers Historic Market Size by Type (2018-2023)
    4.2 Global Central Nervous System Biomarkers Forecasted Market Size by Type (2024-2029)

 5 Central Nervous System Biomarkers Breakdown Data by Application
    5.1 Global Central Nervous System Biomarkers Historic Market Size by Application (2018-2023)
    5.2 Global Central Nervous System Biomarkers Forecasted Market Size by Application (2024-2029)

 6 North America
    6.1 North America Central Nervous System Biomarkers Market Size (2018-2029)
    6.2 North America Central Nervous System Biomarkers Market Growth Rate by Country: 2018 VS 2022 VS 2029
    6.3 North America Central Nervous System Biomarkers Market Size by Country (2018-2023)
    6.4 North America Central Nervous System Biomarkers Market Size by Country (2024-2029)
    6.5 United States
    6.6 Canada

 7 Europe
    7.1 Europe Central Nervous System Biomarkers Market Size (2018-2029)
    7.2 Europe Central Nervous System Biomarkers Market Growth Rate by Country: 2018 VS 2022 VS 2029
    7.3 Europe Central Nervous System Biomarkers Market Size by Country (2018-2023)
    7.4 Europe Central Nervous System Biomarkers Market Size by Country (2024-2029)
    7.5 Germany
    7.6 France
    7.7 U.K.
    7.8 Italy
    7.9 Russia
    7.10 Nordic Countries

 8 Asia-Pacific
    8.1 Asia-Pacific Central Nervous System Biomarkers Market Size (2018-2029)
    8.2 Asia-Pacific Central Nervous System Biomarkers Market Growth Rate by Region: 2018 VS 2022 VS 2029
    8.3 Asia-Pacific Central Nervous System Biomarkers Market Size by Region (2018-2023)
    8.4 Asia-Pacific Central Nervous System Biomarkers Market Size by Region (2024-2029)
    8.5 China
    8.6 Japan
    8.7 South Korea
    8.8 Southeast Asia
    8.9 India
    8.10 Australia

 9 Latin America
    9.1 Latin America Central Nervous System Biomarkers Market Size (2018-2029)
    9.2 Latin America Central Nervous System Biomarkers Market Growth Rate by Country: 2018 VS 2022 VS 2029
    9.3 Latin America Central Nervous System Biomarkers Market Size by Country (2018-2023)
    9.4 Latin America Central Nervous System Biomarkers Market Size by Country (2024-2029)
    9.5 Mexico
    9.6 Brazil

 10 Middle East & Africa
    10.1 Middle East & Africa Central Nervous System Biomarkers Market Size (2018-2029)
    10.2 Middle East & Africa Central Nervous System Biomarkers Market Growth Rate by Country: 2018 VS 2022 VS 2029
    10.3 Middle East & Africa Central Nervous System Biomarkers Market Size by Country (2018-2023)
    10.4 Middle East & Africa Central Nervous System Biomarkers Market Size by Country (2024-2029)
    10.5 Turkey
    10.6 Saudi Arabia
    10.7 UAE

 11 Key Players Profiles
    11.1 Merck
        11.1.1 Merck Company Detail
        11.1.2 Merck Business Overview
        11.1.3 Merck Central Nervous System Biomarkers Introduction
        11.1.4 Merck Revenue in Central Nervous System Biomarkers Business (2018-2023)
        11.1.5 Merck Recent Development
    11.2 Takeda Pharmaceutical
        11.2.1 Takeda Pharmaceutical Company Detail
        11.2.2 Takeda Pharmaceutical Business Overview
        11.2.3 Takeda Pharmaceutical Central Nervous System Biomarkers Introduction
        11.2.4 Takeda Pharmaceutical Revenue in Central Nervous System Biomarkers Business (2018-2023)
        11.2.5 Takeda Pharmaceutical Recent Development
    11.3 Thermo Fisher Scientific
        11.3.1 Thermo Fisher Scientific Company Detail
        11.3.2 Thermo Fisher Scientific Business Overview
        11.3.3 Thermo Fisher Scientific Central Nervous System Biomarkers Introduction
        11.3.4 Thermo Fisher Scientific Revenue in Central Nervous System Biomarkers Business (2018-2023)
        11.3.5 Thermo Fisher Scientific Recent Development
    11.4 Avacta Group
        11.4.1 Avacta Group Company Detail
        11.4.2 Avacta Group Business Overview
        11.4.3 Avacta Group Central Nervous System Biomarkers Introduction
        11.4.4 Avacta Group Revenue in Central Nervous System Biomarkers Business (2018-2023)
        11.4.5 Avacta Group Recent Development
    11.5 Diagenic Asa
        11.5.1 Diagenic Asa Company Detail
        11.5.2 Diagenic Asa Business Overview
        11.5.3 Diagenic Asa Central Nervous System Biomarkers Introduction
        11.5.4 Diagenic Asa Revenue in Central Nervous System Biomarkers Business (2018-2023)
        11.5.5 Diagenic Asa Recent Development
    11.6 Banyan Biomarkers
        11.6.1 Banyan Biomarkers Company Detail
        11.6.2 Banyan Biomarkers Business Overview
        11.6.3 Banyan Biomarkers Central Nervous System Biomarkers Introduction
        11.6.4 Banyan Biomarkers Revenue in Central Nervous System Biomarkers Business (2018-2023)
        11.6.5 Banyan Biomarkers Recent Development
    11.7 Eli Lilly
        11.7.1 Eli Lilly Company Detail
        11.7.2 Eli Lilly Business Overview
        11.7.3 Eli Lilly Central Nervous System Biomarkers Introduction
        11.7.4 Eli Lilly Revenue in Central Nervous System Biomarkers Business (2018-2023)
        11.7.5 Eli Lilly Recent Development
    11.8 Pfizer
        11.8.1 Pfizer Company Detail
        11.8.2 Pfizer Business Overview
        11.8.3 Pfizer Central Nervous System Biomarkers Introduction
        11.8.4 Pfizer Revenue in Central Nervous System Biomarkers Business (2018-2023)
        11.8.5 Pfizer Recent Development
    11.9 Alseres Pharmaceuticals
        11.9.1 Alseres Pharmaceuticals Company Detail
        11.9.2 Alseres Pharmaceuticals Business Overview
        11.9.3 Alseres Pharmaceuticals Central Nervous System Biomarkers Introduction
        11.9.4 Alseres Pharmaceuticals Revenue in Central Nervous System Biomarkers Business (2018-2023)
        11.9.5 Alseres Pharmaceuticals Recent Development
    11.10 Acumen pharmaceuticals
        11.10.1 Acumen pharmaceuticals Company Detail
        11.10.2 Acumen pharmaceuticals Business Overview
        11.10.3 Acumen pharmaceuticals Central Nervous System Biomarkers Introduction
        11.10.4 Acumen pharmaceuticals Revenue in Central Nervous System Biomarkers Business (2018-2023)
        11.10.5 Acumen pharmaceuticals Recent Development
    11.11 EKF Diagnostics
        11.11.1 EKF Diagnostics Company Detail
        11.11.2 EKF Diagnostics Business Overview
        11.11.3 EKF Diagnostics Central Nervous System Biomarkers Introduction
        11.11.4 EKF Diagnostics Revenue in Central Nervous System Biomarkers Business (2018-2023)
        11.11.5 EKF Diagnostics Recent Development
    11.12 Abiant
        11.12.1 Abiant Company Detail
        11.12.2 Abiant Business Overview
        11.12.3 Abiant Central Nervous System Biomarkers Introduction
        11.12.4 Abiant Revenue in Central Nervous System Biomarkers Business (2018-2023)
        11.12.5 Abiant Recent Development
    11.13 Myriad RBM
        11.13.1 Myriad RBM Company Detail
        11.13.2 Myriad RBM Business Overview
        11.13.3 Myriad RBM Central Nervous System Biomarkers Introduction
        11.13.4 Myriad RBM Revenue in Central Nervous System Biomarkers Business (2018-2023)
        11.13.5 Myriad RBM Recent Development
    11.14 Aposense
        11.14.1 Aposense Company Detail
        11.14.2 Aposense Business Overview
        11.14.3 Aposense Central Nervous System Biomarkers Introduction
        11.14.4 Aposense Revenue in Central Nervous System Biomarkers Business (2018-2023)
        11.14.5 Aposense Recent Development

 12 Analyst's Viewpoints/Conclusions

 13 Appendix
    13.1 Research Methodology
        13.1.1 Methodology/Research Approach
        13.1.2 Data Source
    13.2 Disclaimer

Published By : QY Research

Why ‘The Market Reports’

In Business: Pre Sales Support: Post Sales Support: Turn Around Time: Clients Served: Clients Assisted: Client Types: Payment: Partners with: Number of reports: Custom Research: Report Availability: Report Delivery Format: Security:

Latest Life Science Market Reports

Payments Accepted From

Connect with us at

Complete Secure Website

SiteLock